ICICI Venture

ICICI Venture is one of India’s most seasoned mid-market private equity firms, headquartered in Mumbai and deploying $25M+ growth cheques into specialty healthcare and medical devices, including buyouts and growth investments in clinical infrastructure and manufacturing. The firm benefits from ICICI Bank’s broader institutional reach and a long track record of successful exits across consumer, financial services, and healthcare. For founders, ICICI Venture is best understood as a PE consolidator and growth investor for mature healthcare assets rather than a venture growth investor. The right founder is an Indian operator running a $50M+ revenue specialty hospital network, medical device manufacturer, or diagnostic chain with audited financials, durable EBITDA, and a clear path to consolidation, IPO, or strategic exit. AI focus is not a stated priority and the firm’s value-add is operational and financial engineering rather than technology curve bets. Founders running early-stage digital health, software-only plays, or pre-revenue plays should not approach. The cleanest entry path is via a sell-side banker (Avendus, Kotak, JP Morgan India), an ICICI Venture portfolio CEO, or a Big Four healthcare deals partner. In the pitch, lead with audited EBITDA, segment-level economics, regulatory and licensing posture, governance maturity, and a clear consolidation pipeline; come prepared to discuss management equity, board composition, and exit pathways. Caveats: as a PE firm, ICICI Venture will price discipline and underwriting and term sheets carry standard PE governance terms. Cycle times are months, the firm prefers proprietary deal flow, and exit horizons are typically 5-7 years. Indian healthcare regulatory and clinical reimbursement dynamics will be probed thoroughly. Founders should be realistic about valuation discipline given the firm’s underwriting culture and the limited number of strategic acquirers in Indian specialty healthcare.